OS Therapies grants Robert Petit 200,000 options

The award vests in monthly installments only while Robert Petit remains an OS Therapies employee on each applicable vesting date.

Available on EDGAR 10/30/2026 - 09:00 PM EDT Accepted by SEC EDGAR 10/30/2026 - 09:00 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

OS Therapies Inc (OSTX) Chief Medical Officer and Chief Scientific Officer Robert Petit received an award of options to purchase 200,000 shares of common stock on October 22, 2026. The options have a $1.25-per-share exercise price and expire October 22, 2036. They vest in 12 equal installments on each monthly anniversary of the grant date, provided Petit remains an employee on each applicable vesting date.

Insider Trade Summary

Grant/Award: 200,000 shares

Grant/Award 1 txn

Insider PETIT ROBERT

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock options (right to buy) F1	200,000	$0.00	$0.00
Holding	Common Stock	--	--	--

Holdings After Transaction: Stock options (right to buy) — 200,000 contracts (Direct); Common Stock — 200,000 shares (Direct)

Footnotes (1)

1. F1. On October 22, 2026, the reporting person was granted options to purchase 200,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and the issuer's amended and restated 2023 incentive compensation plan. These options vest in 12 equal installments on each monthly anniversary of the date of grant, provided that the reporting person is serving as an employee of the issuer on each applicable vesting date.

Key Figures

Options granted: 200,000 options Exercise price: $1.25 per share Vesting installments: 12 equal installments +1 more

4 metrics

Options granted 200,000 options Granted October 22, 2026

Exercise price $1.25 per share Options to purchase OS Therapies common stock

Vesting installments 12 equal installments On each monthly anniversary of the grant date, subject to continued employment

Expiration date October 22, 2036 Options granted October 22, 2026

Key Terms

stock option award agreement, vest, amended and restated 2023 incentive compensation plan

3 terms

stock option award agreement financial

"terms and conditions of a stock option award agreement"

A stock option award agreement is a legal document that gives a person the right to buy a company’s shares at a fixed price later, with clear rules about when those rights become usable, how long they last, and any conditions for exercising them. For investors it matters because these agreements can increase the total shares outstanding and affect company costs and incentives—like a coupon that can turn into new stock, changing ownership and future stock supply.

vest financial

"These options vest in 12 equal installments"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

amended and restated 2023 incentive compensation plan financial

"issuer's amended and restated 2023 incentive compensation plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many OSTX options did Robert Petit receive?

Robert Petit was granted options to purchase 200,000 shares of OS Therapies common stock on October 22, 2026.

What is the exercise price for Robert Petit's OSTX options?

The options have an exercise price of $1.25 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PETIT ROBERT

(Last) (First) (Middle)

C/O OS THERAPIES INCORPORATED

115 PULLMAN CROSSING ROAD, SUITE 103

(Street)

GRASONVILLE MARYLAND 21638

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OS Therapies Inc [ OSTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								200,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock options (right to buy)	$1.25	10/22/2026		A		200,000		(1)	10/22/2036	Common Stock	200,000	$0	200,000	D

Explanation of Responses:

1. On October 22, 2026, the reporting person was granted options to purchase 200,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and the issuer's amended and restated 2023 incentive compensation plan. These options vest in 12 equal installments on each monthly anniversary of the date of grant, provided that the reporting person is serving as an employee of the issuer on each applicable vesting date.

Remarks:

Robert Petit is the Chief Medical Officer and Chief Scientific Officer of OS Therapies Incorporated.

	/s/ Robert Petit	10/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)